Navigation Links
Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nation's Top Prostate Specialists
Date:1/16/2009

TargetScan(R) Technology passes 3,500-procedure milestone as the system becomes available in more medical centers and private practices across the country

ST. LOUIS, Jan. 16 /PRNewswire/ -- To date, more than 3,500 prostate biopsies and subsequent cancer treatment procedures have been conducted using the proprietary TargetScan(R) technology, adopted by prostate specialists in search of more effective cancer treatments with fewer side effects.

The TargetScan technology has been shown to accurately map the prostate, delivering precise, repeatable biopsies that record results from specific locations within the gland. The ability to target specific locations may deliver optimal cancer treatments while reducing negative side effects, such as erectile dysfunction and incontinence that result from more aggressive cancer therapies.

TargetScan collects 3-D images using a proprietary stationary ultrasound probe; leads physicians in systematically mapping prostate locations; and guides biopsy sampling and/or cancer therapies through needle placement within the defined template map. The original technology was introduced in 2005 and is now used at the nation's top urologic centers, including Washington University, Duke University, Emory University, New York University and the University of Michigan - and is being adopted in private practice by urologists interested in bringing state-of-the-art care to their offices.

"TargetScan is an excellent tool that reliably defines where cancer exists in the prostate and maps the prostate in a reproducible manner so I may accurately follow a patient's progress and cancer status over time," explains James K. Bennett, M.D., a leading urologist in private practice in Atlanta. "This is the future of prostate cancer diagnosis and treatment for men who seek alternatives to extreme surgical treatments and negative side effects."

Gerald L. Andriole, Jr., M.D., Professor and Chief of Urologic Surgery at Washington University School of Medicine in St. Louis is a member of a multi-center team that conducted an evaluation of TargetScan. Their study was published in the British Journal of Urology and showed that TargetScan template guided biopsy technology potentially produces a higher cancer detection rate for first time biopsies and a more accurate assessment of grade. "More accurate biopsies and targeted cancer treatments may help patients achieve better results with fewer negative side effects," says Dr. Andriole.

About Envisioneering Medical Technologies

Envisioneering Medical Technologies, based in St. Louis, Mo., offers technology to support the continuum of care for the prostate - from accurate biopsies to targeted cancer treatment. TargetScan Touch(TM) was introduced in late 2008, incorporating a touch-screen interface with the TargetScan(R) Ultrasound Probe technology platform. For more information please visit www.envisioneeringmedical.com.


'/>"/>
SOURCE Envisioneering Medical Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anthem Blue Cross and Blue Shield Introduces SmartSense, Price-Conscious Plans Targeted at the Uninsured
2. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
3. Experts: Targeted agricultural investments will yield high results, slash poverty in Africa
4. Combining targeted therapy drugs may treat previously resistant tumors
5. Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patients
6. CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured
7. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
8. Targeted radiation therapy can control limited cancer spread
9. Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease
10. Personalizing medicine: New research shows potential of targeted therapies for cancer
11. Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: